Literature DB >> 7760612

Impaired nocturnal secretion of melatonin in coronary heart disease.

P Brugger1, W Marktl, M Herold.   

Abstract

Patients with coronary heart disease have increased nocturnal urinary noradrenaline. Because melatonin suppresses sympathetic activity, we measured serum melatonin concentrations at night (0200 h) in 15 patients with coronary heart disease. Melatonin was significantly lower in the patients than in 10 healthy controls (median 7.8 [interquartile range 6.5-11.8] vs 36.2 [32.2-42.5] pg/mL, p < 0.0001). Thus, impaired nocturnal secretion of melatonin is associated with coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760612     DOI: 10.1016/s0140-6736(95)92600-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 2.  Circadian disruption and SCN control of energy metabolism.

Authors:  Andries Kalsbeek; Frank A Scheer; Stephanie Perreau-Lenz; Susanne E La Fleur; Chun-Xia Yi; Eric Fliers; Ruud M Buijs
Journal:  FEBS Lett       Date:  2011-03-21       Impact factor: 4.124

Review 3.  Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation.

Authors:  Revathy Carnagarin; Vance B Matthews; Lakshini Y Herat; Jan K Ho; Markus P Schlaich
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

4.  Is there diurnal variation of the vestibulosympathetic reflex: implications for orthostatic hypotension.

Authors:  Chester A Ray; Charity L Sauder; Stephanie A Chin-Sang; Jonathan S Cook
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-06       Impact factor: 4.733

Review 5.  Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.

Authors:  Mohsen Imenshahidi; Golamreza Karimi; Hossein Hosseinzadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-30       Impact factor: 3.000

6.  Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.

Authors:  Frank A J L Scheer; Christopher J Morris; Joanna I Garcia; Carolina Smales; Erin E Kelly; Jenny Marks; Atul Malhotra; Steven A Shea
Journal:  Sleep       Date:  2012-10-01       Impact factor: 5.849

7.  MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.

Authors:  Radhika R Tunstall; Praveen Shukla; Anna Grazul-Bilska; Chengwen Sun; Stephen T O'Rourke
Journal:  J Pharmacol Exp Ther       Date:  2010-10-19       Impact factor: 4.030

8.  Urinary melatonin and risk of incident hypertension among young women.

Authors:  John P Forman; Gary C Curhan; Eva S Schernhammer
Journal:  J Hypertens       Date:  2010-03       Impact factor: 4.844

Review 9.  Complementary and alternative medicine for sleep disturbances in older adults.

Authors:  Nalaka S Gooneratne
Journal:  Clin Geriatr Med       Date:  2008-02       Impact factor: 3.076

10.  Urinary levels of melatonin and risk of postmenopausal breast cancer: women's health initiative observational cohort.

Authors:  Susan R Sturgeon; Ashley Doherty; Katherine W Reeves; Carol Bigelow; Frank Z Stanczyk; Judith K Ockene; Simin Liu; JoAnn E Manson; Marian L Neuhouser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-07       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.